CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
暂无分享,去创建一个
Dong-Sheng Cao | Dan Li | Tingjun Hou | Junbo Gao | Jinping Pang | Jun-Jie Ding | Gaoqi Weng | Xin Chai | Hongyan Du | Yu Kang | Dongsheng Cao | Dan Li | Tingjun Hou | Gaoqi Weng | Yu Kang | Jun-Jie Ding | Hongyan Du | Xin Chai | Jinping Pang | Junbo Gao
[1] M. Potashman,et al. Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.
[2] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[3] Nicholas B Rego,et al. 3Dmol.js: molecular visualization with WebGL , 2014, Bioinform..
[4] Richard Lonsdale,et al. Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity , 2017, J. Chem. Inf. Model..
[5] David S. Goodsell,et al. RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..
[6] F. McCormick,et al. RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.
[7] The Uniprot Consortium. UniProt: the universal protein knowledgebase , 2018, Nucleic acids research.
[8] G. Keserű,et al. Covalent fragment libraries in drug discovery. , 2020, Drug discovery today.
[9] Igor V. Tetko,et al. Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..
[10] S. Laufer,et al. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. , 2018, Journal of medicinal chemistry.
[11] Noel S. Wilson,et al. Covalent binders in drug discovery. , 2019, Progress in medicinal chemistry.
[12] P. Bourne,et al. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. , 2017, Journal of medicinal chemistry.
[13] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[14] Evan Bolton,et al. PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..
[15] E. Myers,et al. Basic local alignment search tool. , 1990, Journal of molecular biology.
[16] Han Zhang,et al. Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking , 2019, J. Chem. Inf. Model..
[17] Andrew R. Leach,et al. ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..
[18] J. Falgueyret,et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.
[19] R. Lonsdale,et al. Structure-based design of targeted covalent inhibitors. , 2018, Chemical Society reviews.
[20] N. Gray,et al. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. , 2019, Cell chemical biology.
[21] Kai Zhu,et al. Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..
[22] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[23] William L Todsen. ChemDoodle 6.0 , 2014, J. Chem. Inf. Model..
[24] Wesley M. Botello-Smith,et al. Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors? , 2017, Journal of the American Chemical Society.
[25] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[26] Peng Ding,et al. cBinderDB: a covalent binding agent database , 2017, Bioinform..
[27] A. Olson,et al. Proteome-wide covalent ligand discovery in native biological systems , 2016, Nature.
[28] Matthew Grist,et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). , 2013, Journal of medicinal chemistry.